Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.

Leeman A, Del Pino M, Molijn A, Rodriguez A, Torné A, de Koning M, Ordi J, van Kemenade F, Jenkins D, Quint W.

BJOG. 2017 Aug;124(9):1356-1363. doi: 10.1111/1471-0528.14682.

PMID:
28391609
2.

The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China.

Chen W, Molijn A, Enqi W, Zhang X, Jenkins D, Yu X, Quint W, Schmidt JE, Li J, Pirog E, Liu B, Li Q, Liu X, Li L, Qiao Y; Chinese HPV typing group.

Int J Cancer. 2016 Dec 15;139(12):2687-2697. doi: 10.1002/ijc.30401. Epub 2016 Sep 14.

PMID:
27554015
3.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YK, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WG, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F; VIVIANE Study Group.

Lancet Infect Dis. 2016 Oct;16(10):1154-68. doi: 10.1016/S1473-3099(16)30120-7. Epub 2016 Jun 28.

PMID:
27373900
4.

The complex relationship between human papillomavirus and cervical adenocarcinoma.

Molijn A, Jenkins D, Chen W, Zhang X, Pirog E, Enqi W, Liu B, Schmidt J, Cui J, Qiao Y, Quint W; Chinese HPV Typing Group.

Int J Cancer. 2016 Jan 15;138(2):409-16. doi: 10.1002/ijc.29722. Epub 2015 Sep 3.

5.

Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.

Holl K, Nowakowski AM, Powell N, McCluggage WG, Pirog EC, Collas De Souza S, Tjalma WA, Rosenlund M, Fiander A, Castro Sánchez M, Damaskou V, Joura EA, Kirschner B, Koiss R, O'Leary J, Quint W, Reich O, Torné A, Wells M, Rob L, Kolomiets L, Molijn A, Savicheva A, Shipitsyna E, Rosillon D, Jenkins D.

Int J Cancer. 2015 Dec 15;137(12):2858-68. doi: 10.1002/ijc.29651. Epub 2015 Jul 14.

6.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

7.

Conservative Treatment Seems the Best Choice in Adenocarcinoma In Situ of the Cervix Uteri.

Baalbergen A, Molijn AC, Quint WG, Smedts F, Helmerhorst TJ.

J Low Genit Tract Dis. 2015 Jul;19(3):239-43. doi: 10.1097/LGT.0000000000000114.

PMID:
25943864
8.

Disagreement in high-grade/low-grade intraepithelial neoplasia and high-risk/low-risk HPV infection: clinical implications for anal cancer precursor lesions in HIV-positive and HIV-negative MSM.

Pimenoff VN, Félez-Sánchez M, Tous S, Clavero O, Godínez JM, Klaustermeier J, Saunier M, Molijn A, Alemany L, Quint W, Bosch FX, de Sanjosé S, McCloskey J, Bravo IG.

Clin Microbiol Infect. 2015 Jun;21(6):605.e11-9. doi: 10.1016/j.cmi.2015.02.009. Epub 2015 Feb 17.

9.

The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra.

Geraets DT, Struijk L, Kleter B, Molijn A, van Doorn LJ, Quint WG, Colau B.

J Virol Methods. 2015 Apr;215-216:22-9. doi: 10.1016/j.jviromet.2015.01.001. Epub 2015 Feb 16.

PMID:
25698462
10.

A rare case of HPV-negative cervical squamous cell carcinoma.

Casey S, Harley I, Jamison J, Molijn A, van den Munckhof H, McCluggage WG.

Int J Gynecol Pathol. 2015 Mar;34(2):208-12. doi: 10.1097/PGP.0000000000000132.

PMID:
25675193
11.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

12.

Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.

Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmerón J, Lehtinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner SR, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn LJ, David MP, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Feb;22(2):235-44. doi: 10.1128/CVI.00457-14. Epub 2014 Dec 24.

13.

TEMPORARY REMOVAL: The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra.

Geraets DT, Struijk L, Kleter B, Molijn A, van Doorn L, Quint WG, Colau B.

J Virol Methods. 2014 Dec 2;213C:1. doi: 10.1016/j.jviromet.2014.11.008. [Epub ahead of print]

PMID:
25476446
14.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G; VIVIANE Study Group.

Lancet. 2014 Dec 20;384(9961):2213-27. doi: 10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1.

PMID:
25189358
15.

Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.

Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M; Retrospective International Survey and HPV Time Trends Study Group; Retrospective International Survey and HPV Time Trends Study Group.

J Pathol. 2014 Dec;234(4):441-51. doi: 10.1002/path.4405. Epub 2014 Sep 12.

PMID:
25043390
16.

Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand.

Sykes P, Gopala K, Tan AL, Kenwright D, Petrich S, Molijn A, Chen J.

BMC Infect Dis. 2014 Jul 8;14:374. doi: 10.1186/1471-2334-14-374.

17.

Six-month incidence and persistence of oral HPV infection in HIV-negative and HIV-infected men who have sex with men.

Mooij SH, Boot HJ, Speksnijder AG, Meijer CJ, King AJ, Verhagen DW, de Vries HJ, Quint WG, Molijn A, de Koning MN, van der Sande MA, van der Loeff MF.

PLoS One. 2014 Jun 4;9(6):e98955. doi: 10.1371/journal.pone.0098955. eCollection 2014.

18.

HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases.

Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, Clavero O, Klaustermeier J, Jenkins D, Quint WG, Xavier Bosch F, Alemany L, de Sanjosé S; RIS HPV TT study group.

Mod Pathol. 2014 Dec;27(12):1559-67. doi: 10.1038/modpathol.2014.55. Epub 2014 Apr 25.

19.

Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.

Vintermyr OK, Iversen O, Thoresen S, Quint W, Molijn A, de Souza S, Rosillon D, Holl K.

Gynecol Oncol. 2014 May;133(2):159-66. doi: 10.1016/j.ygyno.2014.03.004. Epub 2014 Mar 11.

PMID:
24631451
20.

Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka.

Karunaratne K, Ihalagama H, Rohitha S, Molijn A, Gopala K, Schmidt JE, Chen J, Datta S, Mehta S.

BMC Cancer. 2014 Feb 21;14:116. doi: 10.1186/1471-2407-14-116.

Supplemental Content

Loading ...
Support Center